Results 71 to 80 of about 9,765 (234)

Viral Pathogens and Pulmonary Fibrosis: EMT‐Driven Mechanisms and Insights From Traditional Chinese Medicine

Reviews in Medical Virology, Volume 36, Issue 2, March 2026.
ABSTRACT Idiopathic pulmonary fibrosis (IPF) is a serious progressive complication of the respiratory system, which is profoundly associated with persistent extracellular matrix (ECM) deposition, fibrosis, and disrupted tissue regeneration. Emerging evidence shows that epithelial–mesenchymal transition (EMT) acts as a key factor in the pathogenesis of ...
Ningzi Zang, Yingxu Wu, Pin Li, Yongming Liu, Shiwen Wang, Jiapeng Leng, Libin Zhan, Xiaodong Lyu, Lijian Pang, Jiaran Wang   +9 more
wiley   +1 more source

A quantitative high-resolution genetic profile rapidly identifies sequence determinants of hepatitis C viral fitness and drug sensitivity.

PLoS Pathogens, 2014
Widely used chemical genetic screens have greatly facilitated the identification of many antiviral agents. However, the regions of interaction and inhibitory mechanisms of many therapeutic candidates have yet to be elucidated.
Hangfei Qi, C Anders Olson, Nicholas C Wu, Ruian Ke, Claude Loverdo, Virginia Chu, Shawna Truong, Roland Remenyi, Zugen Chen, Yushen Du, Sheng-Yao Su, Laith Q Al-Mawsawi, Ting-Ting Wu, Shu-Hua Chen, Chung-Yen Lin, Weidong Zhong, James O Lloyd-Smith, Ren Sun   +17 more
doaj   +1 more source

Approaches to hepatitis C treatment and cure using NS5A inhibitors

Infection and Drug Resistance, 2014
Recent progress in the understanding of hepatitis C virus (HCV) biology and the availability of in vitro models to study its replication have facilitated the development of direct-acting antiviral agents (DAAs) that target specific steps in the viral replication cycle.
Schinazi, Raymond, Kohler,James, Nettles,James, Amblard,Franck, Hurwitz,Selwyn, Bassit,Leda, Stanton,Richard, Ehteshami,Maryam   +7 more
openaire   +4 more sources

Electrosynthesis of Bioactive Chemicals, From Ions to Pharmaceuticals

Advanced Functional Materials, Volume 36, Issue 16, 23 February 2026.
This review discusses recent advances in electrosynthesis for biomedical and pharmaceutical applications. It covers key electrochemical materials enabling precise delivery of ions and small molecules for cellular modulation and disease treatment, alongside catalytic systems for pharmaceutical synthesis.
Gwangbin Lee, Sojin Kim, Myeongeun Lee, Kyoungsuk Jin, Jimin Park   +4 more
wiley   +1 more source

Improvement of ALT decay kinetics by all-oral HCV treatment: Role of NS5A inhibitors and differences with IFN-based regimens.

PLoS ONE, 2017
BackgroundIntracellular HCV-RNA reduction is a proposed mechanism of action of direct-acting antivirals (DAAs), alternative to hepatocytes elimination by pegylated-interferon plus ribavirin (PR).
Valeria Cento, Thi Huyen Tram Nguyen, Domenico Di Carlo, Elisa Biliotti, Laura Gianserra, Ilaria Lenci, Daniele Di Paolo, Vincenza Calvaruso, Elisabetta Teti, Maddalena Cerrone, Dante Romagnoli, Michela Melis, Elena Danieli, Barbara Menzaghi, Ennio Polilli, Massimo Siciliano, Laura Ambra Nicolini, Antonio Di Biagio, Carlo Federico Magni, Matteo Bolis, Francesco Paolo Antonucci, Velia Chiara Di Maio, Roberta Alfieri, Loredana Sarmati, Paolo Casalino, Sergio Bernardini, Valeria Micheli, Giuliano Rizzardini, Giustino Parruti, Tiziana Quirino, Massimo Puoti, Sergio Babudieri, Antonella D'Arminio Monforte, Massimo Andreoni, Antonio Craxì, Mario Angelico, Caterina Pasquazzi, Gloria Taliani, Jeremie Guedj, Carlo Federico Perno, Francesca Ceccherini-Silberstein   +40 more
doaj   +1 more source

The new paradigm of hepatitis C therapy: integration of oral therapies into best practices. [PDF]

, 2013
Emerging data indicate that all-oral antiviral treatments for chronic hepatitis C virus (HCV) will become a reality in the near future. In replacing interferon-based therapies, all-oral regimens are expected to be more tolerable, more effective, shorter ...
Afdhal, NH, Castera, L, Church, DR, Dee, L, Graham, C, Jacobson, IM, Litwin, AH, Mehta, SH, Muir, A, New Paradigm of HCV Therapy Meeting Participants, Poynard, T, Razavi, H, Schooley, RT, Sulkowski, MS, Talal, AH, Thomas, DL, Ward, JW, Zeuzem, S   +17 more
core   +2 more sources

NS5A inhibitors in the treatment of hepatitis C

Journal of Hepatology, 2013
Hepatitis C virus infection is a major health problem worldwide and no vaccine has yet been developed against this virus. In addition, currently approved pharmacotherapies achieve suboptimal cure rates and have side effects that result in non-compliance and premature treatment discontinuation.
openaire   +2 more sources

In Vitro and Clinical Evaluation of Potential Interactions of Bemnifosbuvir with Drug Transporters

The Journal of Clinical Pharmacology, Volume 66, Issue 2, February 2026.
Abstract Bemnifosbuvir is a novel oral guanosine nucleotide prodrug candidate for the treatment of chronic hepatitis C virus infection. Potential drug–drug interactions (DDIs) of bemnifosbuvir as a substrate or perpetrator with regard to ATP‐binding cassette (ABC) and solute carrier (SLC) transporters were evaluated in vitro and in clinical studies ...
Xiao‐Jian Zhou, Alex Vo, Gaetano Morelli, Maureen Montrond, Shannan Lynch, Keith Pietropaolo, Bruce Belanger, Arantxa Horga, Nancy Agrawal, Janet Hammond   +9 more
wiley   +1 more source

Hemoglobin Decrease with Iron Deficiency Induced by Daclatasvir plus Asunaprevir Combination Therapy for Chronic Hepatitis C Virus Genotype 1b. [PDF]

PLoS ONE, 2016
BACKGROUND:Decreased hemoglobin (Hb) level has been supposed to be a relatively rare side effect of a combination therapy against hepatitis C virus that consists of the NS5A inhibitor daclatasvir (DCV) and the NS3/4A protease inhibitor asunaprevir (ASV).
Nobuyuki Matsumoto, Hiroki Ikeda, Ryuta Shigefuku, Nobuhiro Hattori, Tsunamasa Watanabe, Kotaro Matsunaga, Tetsuya Hiraishi, Tomohiro Tamura, Yohei Noguchi, Yasunobu Fukuda, Toshiya Ishii, Chiaki Okuse, Akira Sato, Michihiro Suzuki, Fumio Itoh   +14 more
doaj   +1 more source

NS5A Resistance-Associated Substitutions in Patients with Genotype 1 Hepatitis C Virus:Prevalence and Effect on Treatment Outcome [PDF]

, 2017
Background & Aims The efficacy of NS5A inhibitors for the treatment of patients chronically infected with hepatitis C virus (HCV) can be affected by the presence of NS5A resistance-associated substitutions (RASs).
Brainard, Diana M, Chuang, Wan-Long, Doehle, Brian, Dore, Gregory J, Dvory-Sobol, Hadas, Han, Kwang-Hyub, Hedskog, Charlotte, Jacobson, Ira, Knox, Steven, Mangia, Alessandra, Martin, Ross, McHutchison, John G, Miller, Michael D., Mizokami, Masashi, Mo, Hongmei, Pianko, Stephen, Sulkowski, Mark, Svarovskaia, Evguenia, Yun, Chohee, Zeuzem, Stefan   +19 more
core   +2 more sources